5th ADC Analytical Development Summit Unveils 2026 Agenda to Tackle Emerging Complexity in Next-Generation ADCs
Antibody-drug conjugate analytical development is entering a defining moment. As next-generation modalities, including bispecific ADCs, degrader conjugates, and dual-payload constructs, push the boundaries of innovation, they also introduce invisible heterogeneity, novel impurity profiles, and biologically complex potency challenges that can jeopardize product understanding and regulatory success.
In response to this rapidly evolving landscape, the 5th ADC Analytical Development Summit returns as the only industry-dedicated forum focused exclusively on the analytical complexities of ADC development. The 2026 meeting will convene senior analytical leaders and technical experts committed to advancing robust, high-quality, and regulatory-compliant ADC products.
The 2026 agenda delivers in-depth coverage of the most pressing analytical priorities, including:
- Advanced Drug-to-Antibody Ratio (DAR) characterization
- Impurity identification, monitoring, and control
- Bioassay innovation and potency strategy
- Regulatory expectations and submission readiness
Designed for analytical development, quality control, and CMC professionals, the program equips attendees with practical strategies to strengthen method optimization, deepen product understanding, and confidently address evolving global regulatory requirements. As increasingly complex ADCs advance through clinical pipelines, the need for precise, data-driven analytical approaches has never been greater.
Beyond the technical content, the Summit offers unparalleled peer-to-peer networking with industry leaders shaping the future of ADC analytics, including:
- Francis Poulin, Head of Analytical Development, Takeda Pharmaceutical
- John Valliere Douglas, Senior Director, Analytical Sciences, Pfizer
- Adrienne Wildt, Senior Director of Analytical Development, AbbVie
- Susan Clardy, Director & Head of Analytical Development & QC, Pyxis Oncology
- Stacey Cummins-Bitz, Director, Analytical Development, Eli Lilly
…and many more distinguished analytical scientists from across the ADC landscape.
The 5th ADC Analytical Development Summit provides a unique opportunity to collaborate with peers, refine physicochemical, potency, and impurity analytical strategies, enhance product quality, and ensure accurate DAR assessment for successful regulatory submissions.
For more information and to explore the full 2026 agenda and speaker lineup, visit the event website: adc-analytical.com
Media Contact:
Kate Woodford
Marketing Manager
Hanson Wade Group
info@hansonwade.com
T: +44 (0)20 3141 8700